logo-loader

C4X Discovery 'turns engine right over' with landmark Indivior deal

Published: 12:10 03 Apr 2018 BST

Clive Dix, chief executive of C4X Discovery Holdings plc (LON:C4XD), discusses with Proactive's Andrew Scott their licensing deal with FTSE 250-listed Indivior for its addiction behaviour suppressant, C4X3256.

It is the first major partnership for C4X, which will receive US$10mln up front and a further US$284mln dependent on how successful the drug proves.

C4X Discovery "really well capitalised and focused" heading into new year

  C4X Discovery Holdings PLC (AIM:C4XD) Chief Business Officer Bhavna Hunjan and Chief Scientific Officer Nick Ray speak to Thomas Warner from Proactive after the drug discovery company announced receipt of a US$11 million payment under its US$402 million deal with pharma giant AstraZeneca...

on 4/1/24